Dr. Wayne Speckmann has been working in R&D for over 20 years and is an expert in antibody development and immunoassays.
Antibodies have become one of the most important tools in life science research, allowing the detection, quantitation, and determination of changes in proteins and other molecules with respect to time and subcellular location. MilliporeSigma ZooMAb® antibodies represent a new generation of monoclonal antibodies that are specifically engineered using proprietary technologies that provide state-of-the-art consistency and applications performance. ZooMAb® antibodies are designed with the most user-friendly formulation, handling, and storage features available today and have been validated in multiple immunoassay applications. This platform acquired its unique name because of its proprietary B cell immortalization technology that also allows us to produce monoclonal antibodies from a wide range of species including rabbits, goats, llama, sheep, and more. The monoclonal antibodies produced and selected are subsequently converted into a eukaryotic recombinant expression format. Thus, all ZooMAb® antibodies are offered as affinity purified recombinant proteins for highest reproducibility, purity, and performance. In this webinar, we will highlight the development process of ZooMAb® antibodies, show examples of the outstanding affinity, avidity, and specificity of these antibodies in multiple immunoassays, provide details about the earth friendly format they are provided in, and finally deliver details about future directions as well as custom development opportunities.
1. Learn about advantages of recombinant antibodies in cancer research
2. Learn about ZooMAb antibodies - MilliporeSigma's recombinant monoclonal antibody line